Advancements In Biological Treatment Of Takayasu Arteritis: Efficacy, Safety, And Future Perspectives
DOI:
https://doi.org/10.12775/JEHS.2025.79.57867Keywords
Takayasu’s arteritis (TA), biological treatment, IL-6 inhibitors, TNF-alpha inhibitorsAbstract
Introduction and Objective
Takayasu's arteritis (TAK) is a chronic autoimmune vasculitis that primarily impacts the aorta and its major branches. The standard treatment has been glucocorticoids; however, their prolonged usage can cause severe side effects, and many patients fail to maintain sustained remission. This review aims to assess the recent advances in utilizing biological drugs for treating TAK, with a focus on their efficacy and safety profiles.
Methods
To conduct this review, we analyzed clinical trials, retrospective studies, and case reports. The databases searched included PubMed, MEDLINE, and Scopus utilizing keywords like "Takayasu arteritis," "biological treatment," and specific medication names.
Brief Description of the Current State of Knowledge
Several biological therapies targeting key inflammatory pathways implicated in TAK have demonstrated promise. These include IL-6 inhibitors (tocilizumab), TNF-alpha inhibitors (infliximab, etanercept), and JAK inhibitors (tofacitinib). Clinical research and case reports indicate these therapies can decrease disease activity, facilitate glucocorticoid tapering, and enhance quality of life in patients who do not sufficiently respond to standard treatment. However, concerns remain about long-term safety, including heightened infection risk and paradoxical inflammatory reactions.
Summary
Biological medications represent a major step forward in TAK treatment, providing hope for individuals unresponsive to conventional approaches. However, additional large-scale, randomized controlled trials are needed to establish their long-term efficacy and safety of the treatment.
References
[1] A. Somashekar and Y. T. Leung, “Updates in the diagnosis and management of Takayasu’s arteritis,” Postgrad Med, vol. 135, no. sup1, pp. 14–21, Jan. 2023, doi: 10.1080/00325481.2022.2159723.
[2] A. Singh et al., “Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials.,” Mod Rheumatol, vol. 31, no. 1, pp. 197–204, Jan. 2021, doi: 10.1080/14397595.2020.1724671.
[3] T. Ecclestone and R. A. Watts, “Classification and epidemiology of vasculitis: Emerging concepts,” Best Pract Res Clin Rheumatol, vol. 37, no. 1, p. 101845, Mar. 2023, doi: 10.1016/j.berh.2023.101845.
[4] D. Podgórska, R. Podgórski, D. Aebisher, and P. Dąbrowski, “Takayasu arteritis - epidemiology, pathogenesis, diagnosis and treatment,” J Appl Biomed, vol. 17, no. 1, pp. 20–20, Mar. 2019, doi: 10.32725/jab.2018.005.
[5] M. Samson et al., “Biological treatments in giant cell arteritis & Takayasu arteritis,” Eur J Intern Med, vol. 50, pp. 12–19, Apr. 2018, doi: 10.1016/j.ejim.2017.11.003.
[6] L. Barra, G. Yang, and C. Pagnoux, “Non-glucocorticoid drugs for the treatment of Takayasu’s arteritis: A systematic review and meta-analysis,” Autoimmun Rev, vol. 17, no. 7, pp. 683–693, Jul. 2018, doi: 10.1016/j.autrev.2018.01.019.
[7] T. Mirault and E. Messas, “La maladie de Takayasu,” Rev Med Interne, vol. 37, no. 4, pp. 223–229, Apr. 2016, doi: 10.1016/j.revmed.2015.12.024.
[8] H. Zhang, R. Watanabe, G. J. Berry, L. Tian, J. J. Goronzy, and C. M. Weyand, “Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis,” Circulation, vol. 137, no. 18, pp. 1934–1948, May 2018, doi: 10.1161/CIRCULATIONAHA.117.030423.
[9] D. Pugh et al., “Large-vessel vasculitis,” Nat Rev Dis Primers, vol. 7, no. 1, p. 93, Jan. 2022, doi: 10.1038/s41572-021-00327-5.
[10] J. Deng, B. R. Younge, R. A. Olshen, J. J. Goronzy, and C. M. Weyand, “Th17 and Th1 T-Cell Responses in Giant Cell Arteritis,” Circulation, vol. 121, no. 7, pp. 906–915, Feb. 2010, doi: 10.1161/CIRCULATIONAHA.109.872903.
[11] A. Palermo, C. Marvisi, M. Casali, N. Pipitone, F. Muratore, and C. Salvarani, “Tofacitinib for the treatment of refractory Takayasu’s arteritis: description of 2 cases.,” Clin Exp Rheumatol, vol. 38 Suppl 124, no. 2, pp. 234–235, 2020.
[12] J. Li, M. Li, X. Tian, and X. Zeng, “Tofacitinib in patients with refractory Takayasu’s arteritis,” Rheumatology, vol. 59, no. 11, pp. e95–e98, Nov. 2020, doi: 10.1093/rheumatology/keaa281.
[13] S. Kuwabara, S. Tanimura, S. Matsumoto, H. Nakamura, and T. Horita, “Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis,” Ann Rheum Dis, vol. 79, no. 8, pp. 1125–1126, Aug. 2020, doi: 10.1136/annrheumdis-2019-216606.
[14] U. Rathore, D. R. Thakare, P. Patro, V. Agarwal, A. Sharma, and D. P. Misra, “A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis,” Clin Rheumatol, vol. 41, no. 1, pp. 33–44, Jan. 2022, doi: 10.1007/s10067-021-05973-4.
[15] X. Kong et al., “Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study,” Ann Rheum Dis, vol. 81, no. 1, pp. 117–123, Jan. 2022, doi: 10.1136/annrheumdis-2021-220832.
[16] J. Wang et al., “Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study,” Semin Arthritis Rheum, vol. 55, p. 152018, Aug. 2022, doi: 10.1016/j.semarthrit.2022.152018.
[17] S. R. Ytterberg et al., “Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis,” New England Journal of Medicine, vol. 386, no. 4, pp. 316–326, Jan. 2022, doi: 10.1056/NEJMoa2109927.
[18] D. Saadoun et al., “Th1 and Th17 Cytokines Drive Inflammation in Takayasu Arteritis,” Arthritis & Rheumatology, vol. 67, no. 5, pp. 1353–1360, May 2015, doi: 10.1002/art.39037.
[19] K. Reich et al., “Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study*,” British Journal of Dermatology, vol. 184, no. 3, pp. 425–436, Mar. 2021, doi: 10.1111/bjd.19262.
[20] A. B. Gottlieb et al., “Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data,” Acta Derm Venereol, vol. 102, p. adv00698, Apr. 2022, doi: 10.2340/actadv.v102.563.
[21] N. Venhoff et al., “Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial,” Trials, vol. 22, no. 1, p. 543, Dec. 2021, doi: 10.1186/s13063-021-05520-1.
[22] T. Asano et al., “Efficacy of secukinumab in Takayasu arteritis with myocardial infarction complicated with generalized pustular psoriasis: A case report,” Medicine, vol. 103, no. 51, p. e40994, Dec. 2024, doi: 10.1097/MD.0000000000040994.
[23] X. Tian et al., “Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis,” Arthritis & Rheumatology, vol. 75, no. 8, pp. 1415–1423, Aug. 2023, doi: 10.1002/art.42496.
[24] C. Comarmond et al., “Anti TNF-α in refractory Takayasu’s arteritis: Cases series and review of the literature,” Autoimmun Rev, vol. 11, no. 9, pp. 678–684, Jul. 2012, doi: 10.1016/j.autrev.2011.11.025.
[25] Y. Arita, T. Ishibashi, and Y. Nakaoka, “Current Immunosuppressive Treatment for Takayasu Arteritis,” Circulation Journal, vol. 88, no. 10, p. CJ-23-0780, Sep. 2024, doi: 10.1253/circj.CJ-23-0780.
[26] G. S. Hoffman, P. A. Merkel, R. D. Brasington, D. J. Lenschow, and P. Liang, “Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis,” Arthritis Rheum, vol. 50, no. 7, pp. 2296–2304, Jul. 2004, doi: 10.1002/art.20300.
[27] L. Souabni, K. Ben Abdelghani, S. Jradi, and L. Zakraoui, “Takayasu’s arteritis occurring under TNF-α blockers: a new paradoxical effect?,” BMJ Case Rep, p. bcr2014204226, Nov. 2014, doi: 10.1136/bcr-2014-204226.
[28] N. Mariani, A. So, and B. Aubry-Rozier, “Two cases of Takayasu’s arteritis occurring under anti-TNF therapy,” Joint Bone Spine, vol. 80, no. 2, pp. 211–213, Mar. 2013, doi: 10.1016/j.jbspin.2012.07.015.
[29] M. Osman, S. Aaron, M. Noga, and E. Yacyshyn, “Takayasu’s arteritis progression on anti-TNF biologics: a case series,” Clin Rheumatol, vol. 30, no. 5, pp. 703–706, May 2011, doi: 10.1007/s10067-010-1658-1.
[30] N. Katoh et al., “Takayasu’s Arteritis in a Patient with Crohn’s Disease: An Unexpected Association during Infliximab Therapy,” Internal Medicine, vol. 49, no. 2, pp. 179–182, 2010, doi: 10.2169/internalmedicine.49.2491.
[31] G. Fiorino, S. Danese, B. Pariente, and M. Allez, “Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents,” Autoimmun Rev, vol. 13, no. 1, pp. 15–19, Jan. 2014, doi: 10.1016/j.autrev.2013.06.005.
[32] Y. Seko et al., “Restricted Usage of T-Cell Receptor Vα-Vβ Genes in Infiltrating Cells in Aortic Tissue of Patients With Takayasu’s Arteritis,” Circulation, vol. 93, no. 10, pp. 1788–1790, May 1996, doi: 10.1161/01.CIR.93.10.1788.
[33] H. Yoshifuji, “Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy,” Mod Rheumatol, vol. 29, no. 2, pp. 287–293, Mar. 2019, doi: 10.1080/14397595.2018.1546358.
[34] M. C. Park, S. W. Lee, Y. B. Park, and S. K. Lee, “Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis,” Rheumatology, vol. 45, no. 5, pp. 545–548, May 2006, doi: 10.1093/rheumatology/kei266.
[35] M. Noris, E. Daina, S. Gamba, S. Bonazzola, and G. Remuzzi, “Interleukin-6 and RANTES in Takayasu Arteritis,” Circulation, vol. 100, no. 1, pp. 55–60, Jul. 1999, doi: 10.1161/01.CIR.100.1.55.
[36] C. Salvarani et al., “Tocilizumab: a novel therapy for patients with large-vessel vasculitis,” Rheumatology, vol. 51, no. 1, pp. 151–156, Jan. 2012, doi: 10.1093/rheumatology/ker296.
[37] M. Seitz, S. Reichenbach, H. Bonel, S. Adler, F. Wermelinger, and P. Villiger, “Rapid induction of remission in large vessel vasculitis by IL-6 blockade,” Swiss Med Wkly, Jan. 2011, doi: 10.4414/smw.2011.13156.
[38] S. Unizony et al., “Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica,” Arthritis Care Res (Hoboken), vol. 64, no. 11, pp. 1720–1729, Nov. 2012, doi: 10.1002/acr.21750.
[39] A. Mekinian et al., “Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients,” J Autoimmun, vol. 91, pp. 55–60, Jul. 2018, doi: 10.1016/j.jaut.2018.04.002.
[40] K. Maksimowicz‐McKinnon, T. M. Clark, and G. S. Hoffman, “Limitations of therapy and a guarded prognosis in an american cohort of takayasu arteritis patients,” Arthritis Rheum, vol. 56, no. 3, pp. 1000–1009, Mar. 2007, doi: 10.1002/art.22404.
[41] Y. Nakaoka et al., “Tocilizumab for the Treatment of Patients With Refractory Takayasu Arteritis,” Int Heart J, vol. 54, no. 6, pp. 405–411, 2013, doi: 10.1536/ihj.54.405.
[42] G. S. Hoffman, R. Y. Leavitt, G. S. Kerr, M. Rottem, M. C. Sneller, and A. S. Fauci, “Treatment of glucocorticoid‐resistant or relapsing takayasu arteritis with methotrexate,” Arthritis Rheum, vol. 37, no. 4, pp. 578–582, Dec. 1994, doi: 10.1002/art.1780370420.
[43] “PubChem Compound Summary for , Rituximab.,” National Center for Biotechnology Information, Jan. 2025.
[44] C. Renner, “20 Years of Rituximab Treatment: What have We Learnt?,” Future Oncology, vol. 15, no. 36, pp. 4119–4121, Dec. 2019, doi: 10.2217/fon-2019-0694.
[45] B. F. Hoyer et al., “Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab,” Ann Rheum Dis, vol. 71, no. 1, pp. 75–79, Jan. 2012, doi: 10.1136/ard.2011.153007.
[46] S. Inder, “Immunophenotypic analysis of the aortic wall in Takayasu’s arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions,” Cardiovascular Surgery, vol. 8, no. 2, pp. 141–148, Mar. 2000, doi: 10.1016/S0967-2109(99)00100-3.
[47] H. Wang, J. Ma, Q. Wu, X. Luo, Z. Chen, and L. Kou, “Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis,” J Vasc Surg, vol. 53, no. 1, pp. 174–180, Jan. 2011, doi: 10.1016/j.jvs.2010.06.173.
[48] Y. Nishino et al., “Serum levels of BAFF for assessing the disease activity of Takayasu arteritis.,” Clin Exp Rheumatol, vol. 28, no. 1 Suppl 57, pp. 14–7, 2010.
[49] E. Caltran et al., “Two Takayasu arteritis patients successfully treated with rituximab,” Clin Rheumatol, vol. 33, no. 8, pp. 1183–1184, Aug. 2014, doi: 10.1007/s10067-014-2506-5.
[50] D. Ernst, M. Greer, M. Stoll, D. Meyer-Olson, R. E. Schmidt, and T. Witte, “Remission Achieved in Refractory Advanced Takayasu Arteritis Using Rituximab,” Case Rep Rheumatol, vol. 2012, pp. 1–4, 2012, doi: 10.1155/2012/406963.
[51] H. M. Walters et al., “Takayasu Arteritis Presenting in the Context of Active Tuberculosis,” Journal of Clinical Rheumatology, vol. 19, no. 6, pp. 344–347, Sep. 2013, doi: 10.1097/RHU.0b013e31829ce750.
[52] T. Mutoh et al., “Refractory Takayasu arteritis successfully treated with rituximab: case-based review,” Rheumatol Int, vol. 39, no. 11, pp. 1989–1994, Nov. 2019, doi: 10.1007/s00296-019-04390-w.
[53] M. B. O’Connor, N. O’Donovan, U. Bond, and M. J. Phelan, “Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant,” BMJ Case Rep, p. bcr2016217313, Jan. 2017, doi: 10.1136/bcr-2016-217313.
[54] M. Ahmed et al., “Refractory Case of Takayasu Arteritis in a Young Woman: A Clinical Challenge,” Cureus, Nov. 2016, doi: 10.7759/cureus.872.
[55] S. Kim et al., “Direct brain involvement of Takayasu arteritis treated with rituximab and infliximab: a case report,” encephalitis, vol. 2, no. 1, pp. 9–13, Jan. 2022, doi: 10.47936/encephalitis.2021.00108.
[56] G. Pazzola et al., “Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature,” Rheumatology, vol. 57, no. 7, pp. 1151–1155, Jul. 2018, doi: 10.1093/rheumatology/kex249.
[57] D. Nakagomi, A. Kronbichler, T. Witte, A. J. Mohammad, and D. R. W. Jayne, “Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature,” Rheumatology, vol. 57, no. 7, pp. 1309–1310, Jul. 2018, doi: 10.1093/rheumatology/kex493.
[58] A. Mekinian et al., “Effectiveness and safety of rituximab in Takayasu arteritis: a multicenter retrospective study.,” Joint Bone Spine, vol. 91, no. 2, p. 105658, Mar. 2024, doi: 10.1016/j.jbspin.2023.105658.
[59] A. Sugita et al., “Takayasu’s arteritis in a girl with steroid‐dependent nephrotic syndrome: Could rituximab be the culprit?,” Nephrology, vol. 26, no. 8, pp. 693–694, Aug. 2021, doi: 10.1111/nep.13870.
[60] M. Samson et al., “Biological treatments in giant cell arteritis & Takayasu arteritis,” Eur J Intern Med, vol. 50, pp. 12–19, Apr. 2018, doi: 10.1016/j.ejim.2017.11.003.
[61] C. M. Weyand, B. R. Younge, and J. J. Goronzy, “IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis,” Curr Opin Rheumatol, vol. 23, no. 1, pp. 43–49, Jan. 2011, doi: 10.1097/BOR.0b013e32833ee946.
[62] C. Terao, H. Yoshifuji, T. Nakajima, N. Yukawa, F. Matsuda, and T. Mimori, “Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application,” Scand J Rheumatol, vol. 45, no. 1, pp. 80–82, Jan. 2016, doi: 10.3109/03009742.2015.1060521.
[63] Y. Gon et al., “Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab,” Mod Rheumatol, vol. 31, no. 3, pp. 678–683, May 2021, doi: 10.1080/14397595.2020.1800560.
[64] R. Yachoui, M. Kreidy, M. Siorek, and R. Sehgal, “Successful treatment with ustekinumab for corticosteroid- and immunosuppressant-resistant Takayasu’s arteritis,” Scand J Rheumatol, vol. 47, no. 3, pp. 246–247, May 2018, doi: 10.1080/03009742.2017.1278788.
[65] S.-J. Saur, M. Horger, and J. Henes, “Successful treatment with the IL12/IL23 antagonist ustekinumab in a patient with refractory Takayasu arteritis,” Rheumatol Adv Pract, vol. 5, no. 1, Jan. 2021, doi: 10.1093/rap/rkaa082.
[66] R. Korhonen and E. Moilanen, “Abatacept, a Novel CD80/86–CD28 T Cell Co‐stimulation Modulator, in the Treatment of Rheumatoid Arthritis,” Basic Clin Pharmacol Toxicol, vol. 104, no. 4, pp. 276–284, Apr. 2009, doi: 10.1111/j.1742-7843.2009.00375.x.
[67] C. A. Langford et al., “A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis,” Arthritis & Rheumatology, vol. 69, no. 4, pp. 846–853, Apr. 2017, doi: 10.1002/art.40037.
[68] M. Maz et al., “2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis,” Arthritis Care Res (Hoboken), vol. 73, no. 8, pp. 1071–1087, Aug. 2021, doi: 10.1002/acr.24632.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aleksandra Cygnarowicz, Oliwia Maciaszek, Mikołaj Biskupski , Mariola Turemka, Marianna Chmiel, Artur Tumiński, Aneta Mandziuk, Krystyna Zabojska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 183
Number of citations: 0
